Events and Presentations
Immunic's Multiple Sclerosis R&D Day in New York City
Vidofludimus Calcium’s Profile and Positioning as a Potentially Groundbreaking Multiple Sclerosis Therapy
Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer; Jason Tardio, M.B.A., Chief Operating Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, was joined by two of the MS industry’s renowned experts to discuss the MS landscape as well as Immunic’s orally available lead-asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) and its potential to become the treatment of choice for both relapsing and progressive MS patients.
- Date: Tuesday, September 10, 2024
- Time: 10:30 am to 12:30 pm ET, followed by a networking lunch
- Featured Experts:
- Francesca Montarolo, Ph.D., Senior Post-Doc Researcher, Neuroscience Institute Cavalieri Ottolenghi (NICO) and University of Turin, Italy
- Amit Bar-Or, M.D., FRCPC, Melissa and Paul Anderson Distinguished Chair, Director, Center for Neuroinflammation and Experimental Therapeutics, Chief, Multiple Sclerosis Division, Department of Neurology, Perelman School of Medicine, University of Pennsylvania
